At GSK’s Request, FDA Rescinds Drug That Trump Touted To Treat Autism Bloomberg: FDA Withdraws GSK’s Wellcovorin Approval For Autism Treatment Use US regulators have withdrawn their approval of a GSK Plc drug that the Trump administration had promoted as a treatment for autism, adding another twist to the unusual story of a decades-old drug
GSK again pulls application for leucovorin, touted by FDA as . . . - BioSpace GSK has withdrawn an approval application for Wellcovorin, a decades-old drug that late last year gained renewed attention after the members of the Trump administration publicly suggested it has the potential to treat autism symptoms
GSK Reportedly Pulls Application For Drug Touted By Trump . . . - NewsBreak UK drugmaker GSK Plc (GSK) has reportedly withdrawn its application for the drug leucovorin calcium touted by President Trump as a potential treatment for autism According to a report from the Wall Street Journal on Thursday, GSK asked the U S Food and Drug Administration to pull its application for leucovorin calcium because it doesn’t market the medicine The company hasn’t sold the
FDA withdraws GSK’s approval of drug touted as autism treatment U S regulators have withdrawn their approval of a GSK Plc drug that the Trump administration had promoted as a treatment for autism, adding another twist to the unusual story of a decades-old drug The Food and Drug Administration is pulling
GSK (GSK) Withdraws Leucovorin Calcium Application from FDA - GuruFocus GSK (GSK) has decided to retract its submission for leucovorin calcium, a drug previously highlighted by former President Trump as a potential treatment for autism This decision comes just a few months after the pharmaceutical company filed the application at the behest of health authorities
GSK Withdraws Autism Drug Application - intellectia. ai Application Withdrawal: GSK has requested the U S FDA to withdraw its application for leucovorin calcium, a drug previously touted by President Trump as a potential autism treatment, indicating the company's negative outlook on the drug's market potential